According to Enwei Pharmaceutical's announcement, the company recently received a letter from the controlling shareholder Enwei Group and Chengdu Ruijinheng, a shareholder holding 5% or more of the shares. The two pledged 840,000 shares and 1.88,000 shares of the company's total share capital respectively on August 25, 2026, accounting for 0.82% and 1.93% of the company's total share capital. The use of the pledge was for its own production and operation, and the pledge expiration date was the date of application for cancellation of the pledge registration. As of the disclosure date of the announcement, the above shareholders and their concerted actions pledged a total of 497.68,800 shares, accounting for 74.10% of their shares and 48.37% of the company's total share capital.

According to Enwei Pharmaceutical's announcement, the company recently received a letter from the controlling shareholder Enwei Group and Chengdu Ruijinheng, a shareholder holding 5% or more of the shares. The two pledged 840,000 shares and 1.88,000 shares of the company's total share capital respectively on August 25, 2026, accounting for 0.82% and 1.93% of the company's total share capital. The use of the pledge was for its own production and operation, and the pledge expiration date was the date of application for cancellation of the pledge registration. As of the disclosure date of the announcement, the above shareholders and their concerted actions pledged a total of 497.68,800 shares, accounting for 74.10% of their shares and 48.37% of the company's total share capital.